View in EDS

MO1-2 Safety profile of LIGHT-NING 3rd interim analysis: 1L nivolumab + ipilimumab +/− chemotherapy for metastatic NSCLC.

Saved in:
Bibliographic Details
Title: MO1-2 Safety profile of LIGHT-NING 3rd interim analysis: 1L nivolumab + ipilimumab +/− chemotherapy for metastatic NSCLC.
Authors: Azuma, K.1 (AUTHOR), Imai, H.2 (AUTHOR), Yamaguchi, T.3 (AUTHOR), Kijima, T.4 (AUTHOR), Kishi, K.5 (AUTHOR), Fujita, K.6 (AUTHOR), Saito, H.7 (AUTHOR), Shiraishi, Y.8 (AUTHOR), Tanizaki, J.9 (AUTHOR), Takashima, Y.10 (AUTHOR), Tambo, Y.11 (AUTHOR), Watanabe, S.12 (AUTHOR), Hataji, O.13 (AUTHOR), Toi, Y.14 (AUTHOR), Fukuhara, T.15 (AUTHOR), Ohsugi, T.16 (AUTHOR), Kuroda, H.17 (AUTHOR), Ohe, Y.18 (AUTHOR), Horinouchi, H.18 (AUTHOR)
Source: Annals of Oncology. Oct2024:Supplement 3, Vol. 35, pS1328-S1328. 1p.
Database: Academic Search Ultimate
FullText Text:
  Availability: 0
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 180495587
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: MO1-2 Safety profile of LIGHT-NING 3rd interim analysis: 1L nivolumab + ipilimumab +/− chemotherapy for metastatic NSCLC.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Azuma%2C+K%2E%22">Azuma, K.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Imai%2C+H%2E%22">Imai, H.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Yamaguchi%2C+T%2E%22">Yamaguchi, T.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kijima%2C+T%2E%22">Kijima, T.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kishi%2C+K%2E%22">Kishi, K.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fujita%2C+K%2E%22">Fujita, K.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Saito%2C+H%2E%22">Saito, H.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Shiraishi%2C+Y%2E%22">Shiraishi, Y.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tanizaki%2C+J%2E%22">Tanizaki, J.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Takashima%2C+Y%2E%22">Takashima, Y.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tambo%2C+Y%2E%22">Tambo, Y.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Watanabe%2C+S%2E%22">Watanabe, S.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hataji%2C+O%2E%22">Hataji, O.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Toi%2C+Y%2E%22">Toi, Y.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fukuhara%2C+T%2E%22">Fukuhara, T.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ohsugi%2C+T%2E%22">Ohsugi, T.</searchLink><relatesTo>16</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kuroda%2C+H%2E%22">Kuroda, H.</searchLink><relatesTo>17</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ohe%2C+Y%2E%22">Ohe, Y.</searchLink><relatesTo>18</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Horinouchi%2C+H%2E%22">Horinouchi, H.</searchLink><relatesTo>18</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. Oct2024:Supplement 3, Vol. 35, pS1328-S1328. 1p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=180495587
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.annonc.2024.07.515
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 1
        StartPage: S1328
    Titles:
      – TitleFull: MO1-2 Safety profile of LIGHT-NING 3rd interim analysis: 1L nivolumab + ipilimumab +/− chemotherapy for metastatic NSCLC.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Azuma, K.
      – PersonEntity:
          Name:
            NameFull: Imai, H.
      – PersonEntity:
          Name:
            NameFull: Yamaguchi, T.
      – PersonEntity:
          Name:
            NameFull: Kijima, T.
      – PersonEntity:
          Name:
            NameFull: Kishi, K.
      – PersonEntity:
          Name:
            NameFull: Fujita, K.
      – PersonEntity:
          Name:
            NameFull: Saito, H.
      – PersonEntity:
          Name:
            NameFull: Shiraishi, Y.
      – PersonEntity:
          Name:
            NameFull: Tanizaki, J.
      – PersonEntity:
          Name:
            NameFull: Takashima, Y.
      – PersonEntity:
          Name:
            NameFull: Tambo, Y.
      – PersonEntity:
          Name:
            NameFull: Watanabe, S.
      – PersonEntity:
          Name:
            NameFull: Hataji, O.
      – PersonEntity:
          Name:
            NameFull: Toi, Y.
      – PersonEntity:
          Name:
            NameFull: Fukuhara, T.
      – PersonEntity:
          Name:
            NameFull: Ohsugi, T.
      – PersonEntity:
          Name:
            NameFull: Kuroda, H.
      – PersonEntity:
          Name:
            NameFull: Ohe, Y.
      – PersonEntity:
          Name:
            NameFull: Horinouchi, H.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 10
              Text: Oct2024:Supplement 3
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 09237534
          Numbering:
            – Type: volume
              Value: 35
          Titles:
            – TitleFull: Annals of Oncology
              Type: main
ResultId 1